QNSI

Pharma & life sciences | Modelled case study

Prioritize harvest-now-decrypt-later risk in drug-discovery data

Which target, compound, genomic, and partnership datasets retain economic value past current encryption assumptions?

Accountable ownersResearch CISO · Intellectual Property Counsel · Data Platform
Scenario typeComposite model
Required outputDecision artifact

The modelled organisation

A recognisable problem reaches the operating agenda

This composite scenario follows the Research CISO · Intellectual Property Counsel · Data Platform functions. It is grounded in the cited problem context but does not identify a real customer.

Operating environment

A life-sciences organisation moves regulated and commercially sensitive data through instruments, laboratories, research partners, trial platforms, archives, and submissions.

What is at stake

Loss of provenance or long-term confidentiality can undermine a study, expose valuable research, delay a submission, or make a regulated record indefensible.

Situation

Research repositories are classified by project secrecy but rarely by confidentiality horizon and the cryptography protecting transfers, notebooks, backups, and partner exchanges.

Event that forces action

A strategic research partnership, data-lake consolidation, or quantum-readiness programme.

Concrete system boundary

Systems this case study puts in scope

The model is specific about the operational surfaces that must be discovered, changed, or independently checked.

01

target and compound datasets

02

genomic and assay data

03

partner transfer channels

04

research archives and backups

Modelled case study walkthrough

How this organisation would use QNSI

The walkthrough connects the real-world problem to a bounded QNSI contribution and an independently reviewable result.

01

Recognise the operating condition

Research repositories are classified by project secrecy but rarely by confidentiality horizon and the cryptography protecting transfers, notebooks, backups, and partner exchanges.

02

Frame the decision the owners must make

Which target, compound, genomic, and partnership datasets retain economic value past current encryption assumptions?

03

Apply QNSI to the controlled boundary

Join QNSI crypto discovery with data owners, patent milestones, collaboration paths, and sensitivity duration.

04

Leave the team with a concrete result

An R&D quantum-exposure portfolio ranking datasets by value horizon, capture surface, and remediation option.

05

Prove the result in the organisation's environment

Research and legal owners decide data value, export controls, collaboration constraints, and acceptable re-protection methods.

What useful success looks like

A decision artifact plus proof from the real environment

The model stops at a target result. It becomes an actual case study only when a customer produces and independently validates this evidence in production.

Decision artifact

An R&D quantum-exposure portfolio ranking datasets by value horizon, capture surface, and remediation option.

Independent validation boundary

Research and legal owners decide data value, export controls, collaboration constraints, and acceptable re-protection methods.

Real-world problem grounding

Primary sources behind the model

These sources establish the external requirement, failure mode, or risk context used to model this case. They do not endorse HEOSSI or prove that QNSI completed the scenario.

Customer evidence status

This is modelled, not a customer claim

The organisation is a composite and the result is a target state. This page does not prove a deployment, customer outcome, certification, legal conclusion, regulator endorsement, or completed control.

QNSI privacy choices

Necessary storage keeps the site secure. With your permission, privacy-bounded analytics help HEOSSI understand pages, journeys, and campaign outcomes. No advertising profiles are created.

Cookie policy